Correlation Between Invizyne Technologies and Aquestive Therapeutics

Can any of the company-specific risk be diversified away by investing in both Invizyne Technologies and Aquestive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Invizyne Technologies and Aquestive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Invizyne Technologies Common and Aquestive Therapeutics, you can compare the effects of market volatilities on Invizyne Technologies and Aquestive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Invizyne Technologies with a short position of Aquestive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Invizyne Technologies and Aquestive Therapeutics.

Diversification Opportunities for Invizyne Technologies and Aquestive Therapeutics

0.22

Correlation Coefficient

Invizyne Technologies  Aquestive Therapeutics

Modest diversification

The 3 months correlation between Invizyne and Aquestive is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Invizyne Technologies Common and Aquestive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aquestive Therapeutics and Invizyne Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Invizyne Technologies Common are associated (or correlated) with Aquestive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aquestive Therapeutics has no effect on the direction of Invizyne Technologies i.e., Invizyne Technologies and Aquestive Therapeutics go up and down completely randomly.

Pair Corralation between Invizyne Technologies and Aquestive Therapeutics

Given the investment horizon of 90 days Invizyne Technologies Common is expected to generate 2.18 times more return on investment than Aquestive Therapeutics. However, Invizyne Technologies is 2.18 times more volatile than Aquestive Therapeutics. It trades about 0.34 of its potential returns per unit of risk. Aquestive Therapeutics is currently generating about -0.1 per unit of risk. If you would invest  865.00  in Invizyne Technologies Common on September 17, 2024 and sell it today you would earn a total of  652.00  from holding Invizyne Technologies Common or generate 75.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	35.38%
Values	Daily Returns

Invizyne Technologies Common  vs.  Aquestive Therapeutics

Invizyne Technologies

Risk-Adjusted Performance

26 of 100

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Invizyne Technologies Common are ranked lower than 26 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Invizyne Technologies exhibited solid returns over the last few months and may actually be approaching a breakup point.

Aquestive Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Invizyne Technologies and Aquestive Therapeutics

The main advantage of trading using opposite Invizyne Technologies and Aquestive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Invizyne Technologies position performs unexpectedly, Aquestive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aquestive Therapeutics will offset losses from the drop in Aquestive Therapeutics' long position.

The idea behind Invizyne Technologies Common and Aquestive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.